Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables - Other: 2012-2025

Historic Receivables - Other for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $11.2 million.

  • Ascendis Pharma A's Receivables - Other fell 33.17% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 33.17%. This contributed to the annual value of $10.2 million for FY2024, which is 50.56% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Receivables - Other of $11.2 million as of Q3 2025, which was up 23.23% from $9.1 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Receivables - Other high stood at $32.0 million for Q2 2024, and its period low was $8.7 million during Q1 2021.
  • Its 3-year average for Receivables - Other is $17.8 million, with a median of $16.8 million in 2024.
  • Per our database at Business Quant, Ascendis Pharma A's Receivables - Other skyrocketed by 353.39% in 2021 and then slumped by 71.56% in 2025.
  • Ascendis Pharma A's Receivables - Other (Quarterly) stood at $23.0 million in 2021, then slumped by 43.04% to $13.1 million in 2022, then spiked by 56.93% to $20.5 million in 2023, then plummeted by 51.19% to $10.0 million in 2024, then crashed by 33.17% to $11.2 million in 2025.
  • Its last three reported values are $11.2 million in Q3 2025, $9.1 million for Q2 2025, and $9.0 million during Q1 2025.